<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116203</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00059201</org_study_id>
    <nct_id>NCT04116203</nct_id>
  </id_info>
  <brief_title>Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS)</brief_title>
  <acronym>PCOS</acronym>
  <official_title>Dietary Fish Oil Intervention in Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Women and Children's Health Research Institute, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alberta Diabetes Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective in this proposed study is to determine the effect of dietary fish oil
      supplementation compared to standard care metformin treatment, and fish oil in combination
      with metformin on plasma lipids and apoB-remnant lipoprotein metabolism in overweight-obese
      young women with PCOS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Objectives;

        1. To determine the effect of dietary fish oil supplementation, metformin, and fish oil in
           combination with metformin on fasting and non-fasting plasma TG, apoB48 and
           apoB100-lipoprotein concentrations.

        2. To determine the physiological mechanisms associated with the effect of dietary fish oil
           supplementation and metformin on in vivo plasma lipid and apoB-lipoprotein kinetics. We
           will quantitate the in vivo production and kinetics of plasma TG, apoB48 and
           apoB100-lipoproteins in plasma and isolated lipoprotein fractions, using established
           methods.

        3. To explore the effects of dietary fish oil supplementation, metformin and fish oil in
           combination with metformin, on plasma insulin and testosterone, and the association with
           changes in plasma lipids and apoB-lipoprotein metabolism.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    waiting for additional funding to complete trial
  </why_stopped>
  <start_date type="Actual">June 30, 2016</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Outcomes at 6 and 12 weeks will be compared to baseline values to determine the efficacy of interventions. Participants will act as their own control in each intervention</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is a randomized open-label parallel study in overweight/obese young women with PCOS, in which the participant will be randomly assigned to one of three treatment arms</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Triglycerides and apoB-lipoprotein remnants in non-fasting and fasted state</measure>
    <time_frame>At baseline and postintervention at 12 weeks</time_frame>
    <description>reported as mean +/- SEM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma insulin and glucose</measure>
    <time_frame>At baseline and postintervention at 12 weeks</time_frame>
    <description>reported as mean +/- SEM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma hormones, testosterone, SHBG, Estrogen</measure>
    <time_frame>At baseline and postintervention at 12 weeks</time_frame>
    <description>reported as mean +/- SEM</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Lipid Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Fish Oil</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Fish oil capsules 1200mg 6 tablets/day 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Metformin tablets (500 mg) 2/day 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish Oil and Metformin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Combo of other 2 arms</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Manufacturer's standard 500 mg. Submission Control No.:128147</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Metformin Hydrochloride Oral Antihyperglycemic Agent.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Fish Oil and Metformin</intervention_name>
    <description>Combo of 2 other arms</description>
    <arm_group_label>Fish Oil and Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil</intervention_name>
    <description>NPN: 80028808 Licence Holder: WN Pharmaceuticals Ltd Dosage Form: Capsule, soft Recommended Route of Administration: Oral</description>
    <arm_group_label>Fish Oil</arm_group_label>
    <other_name>Fish Oil; Fish Oil 1200 Mg; Omega-3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Age at time of enrollment &gt; 18 to &lt;30 years

          -  Diagnosis of PCOS: clinical and/or biochemical hyperandrogenemia and menstrual
             dysfunction and the exclusion of other disorders.

          -  Overweight-obese (BMI &gt;25 kg/m2) high-risk metabolically-resistant young women.

          -  Elevated fasting plasma TG (&gt;150 mg/dL) and apoB48-remnant cholesterol lipoproteins
             (&gt;20 ug/ml).

          -  Impaired insulin sensitivity (glucose 100-125 mg/dL and/or insulin &gt;15 (uM/ml); and

          -  May be diagnosed with T2D (blood glucose &gt;126 mg/dL).

        Exclusion Criteria:

          -  Pregnancy

          -  Lactating women

          -  Recent illness that the investigator determines to pose a potential risk for the
             participant

          -  Concomitant medications that influence metabolism (e.g. statins)

          -  Excessive alcohol consumption, as determined by the investigator.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The focus of this study is on overweight-obese high-risk metabolically-resistant young women (aged 18-30 yrs) newly diagnosed with PCOS</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donna F Vine, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>9-111 Endocrinology Department, UofA Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2-004 Li Ka Shing Centre, UofA</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Vine DF, Wang Y, Jetha MM, Ball GD, Proctor SD. Impaired ApoB-Lipoprotein and Triglyceride Metabolism in Obese Adolescents With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2017 Mar 1;102(3):970-982. doi: 10.1210/jc.2016-2854.</citation>
    <PMID>27997268</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Donna Vine</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>metabolic and cardiovascular diseases</keyword>
  <keyword>diabetes</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There will be no sharing with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

